CSF-01 Announcement

by | Mar 25, 2024 | LM

BREAKING NEWS: Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic > Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and...

IR Events

by | Mar 21, 2024 | Uncategorized

Want to hear the latest milestones from our team? We have replays of all our events and earnings calls on our website at IR.PlusTherapeutics.com/Events. Questions about any of the recorded events? Contact us at https://ir.plustherapeutics.com/resources/contact-ir...

Head for the Cure Austin

by | Mar 18, 2024 | Uncategorized

Join some of the Plus Therapeutics team at the @HeadfortheCure 5K in Austin, TX on March 24! They will be out supporting the local community, cancer research, and “Defeating Brain Cancer Step by Step.” We hope to see you there 🏃🏃‍♂️🏃‍♀️ Event information:...

Corporate Presentation

by | Mar 13, 2024 | Uncategorized

AVAILABLE NOW: The new Plus Therapeutics corporate presentation, which reflects our current data, milestones, and pipeline, is on our website. View it directly here: https://bit.ly/3PiHClj Questions about anything or interested in learning more? Visit our website at...

LM Cohort 5 Completion

by | Mar 11, 2024 | LM

BREAKING NEWS! We have completed dosing in Cohort 5 of our ongoing ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases, with a total of 18 patients have been dosed in the trial to date. The trial is STILL ENROLLING and accepting new...